Kjeld-Håkon Nilsen • 1972 • Hylkje • 11 roles • 11 shareholdings

This website uses cookies to enhance the user experience.

Roles

Management

Name	Role	Total operating income	Total equity	Shares
K KHN HOLDING AS	Managing Director/CEO	-	2,009,708	100 % directly
L LANI REVISJON AS	Managing Director/CEO	-	533,851	100 % indirectly
J JANDERSEN KAPITAL AS	Managing Director/CEO	-	-29,685,244	50 % indirectly

Boards

Name	Role	Total operating income	Total equity	Shares
K KHN HOLDING AS	Chairman	-	2,009,708	100 % directly
L LANI REVISJON AS	Chairman	-	533,851	100 % indirectly
J JANDERSEN KAPITAL AS	Board Member	-	-29,685,244	50 % indirectly
A ADJUVANT PARTNERS AS	Chairman	-	183,020	25 % indirectly
F FINANCIAL ADJUVANT AS	Chairman	-	552,058	8.33 % indirectly
H HUBRO THERAPEUTICS AS	Board Member	-	36,467,975	5.01 % indirectly
S SAMEIET SKAKKEFOSSEN	Board Member	-	-	-
T TORVUND REVISJON AS	Alternate Member	3,805,805	2,138,133	-

Last update: Apr 13, 2023

Related industries1

Professional, scientific and technical activities

Direct relationships5

GN
Gaute Toft Næspe1980
FINANCIAL ADJUVANT AS, ADJUVANT PARTNERS AS
IN
Ingmar Nilsen1948
KHN HOLDING AS, LANI REVISJON AS
KA
Kjetil Myrlid Aasen1975
JANDERSEN KAPITAL AS
KC
Kim Christensen1979
SAMEIET SKAKKEFOSSEN
GA
Gunvor Aalvik1964
SAMEIET SKAKKEFOSSEN

Shares owned by Kjeld-Håkon Langeland Nilsen

Name	Share class	Total operating income	Total equity	Share
K KHN HOLDING AS	Ordinære aksjer	0	2,009,708	100 % directly
L LANI REVISJON AS		0	533,851	100 % indirectly
J JANDERSEN KAPITAL AS		0	-29,685,244	50 % indirectly
A ADJUVANT PARTNERS AS		0	183,020	25 % indirectly
F FINANCIAL ADJUVANT AS		0	552,058	8.33 % indirectly
H HUBRO THERAPEUTICS AS		0	36,467,975	5.01 % indirectly
N NEXTERA AS		12,650,318	14,802,788	0.73 % indirectly
A ADJUTEC PHARMA AS		7,333,247	18,067,485	0.72 % indirectly
P PCI BIOTECH AS		2,990,000	36,260,000	0.59 % indirectly
P PCI BIOTECH HOLDING ASA	NO0010405640	0	78,423,000	0.03 % directly 0.03 % indirectly 0.56 %
U ULTIMOVACS ASA	NO0010851603	0	309,373,000	< 0.01 % directly

Limited to direct ownership positions of 0.5% or more.

Last update: May 24, 2024